CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Sodium chenodeoxycholate (NaCDC) +1 moredrug
Likely dose
Sodium chenodeoxycholate (NaCDC) 1000 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00912301
NCT00912301Phase 2Completed
CompareCT.gov

Effect of Chenodeoxycholic Acid on Gastrointestinal Transit and Colonic Functions in Health and Constipation-predominant Irritable Bowel Syndrome (IBS-C)

Mayo Clinic·interventional·Posted Jun 3, 2009·Updated Jul 2, 2012

In Brief

A Phase 2 clinical trial evaluating Sodium chenodeoxycholate (NaCDC) and Placebo for Constipation-predominant Irritable Bowel Syndrome. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConstipation-predominant Irritable Bowel Syndrome
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Research Resources (NCRR)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 3, 2009
Enrollment StartApr 1, 2009
Primary CompletionNov 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.1 years ago

Interventions

Sodium chenodeoxycholate (NaCDC)drug

500 or 1000 milligrams NaCDC per day each for a period of 4 days

Placeboother

Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.